Efficacy and safety of Xuebijing injection combined with phenolamine and dobutamine in the treatment of severe pneumonia complicated by heart failure / 中国基层医药

ABSTRACT

Objective:To investigate the efficacy and safety of Xuebijing injection combined with phentolamine and dobutamine for the treatment of severe pneumonia complicated by heart failure. Methods:A total of 200 patients with severe pneumonia complicated by heart failure treated in Hangzhou Ninth People's Hospital from January 2017 to December 2019 were included in this study. They were randomly allocated into the control and observation groups ( n = 100/group). The control group was treated with phentolamine and dobutamine. The observation group was treated with Xuebijing injection combined with phenolamine and dobutamine. Clinical efficacy, changes in C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), left ventricular ejection fraction (LVEF), cardiac troponin I (cTnI), and B-type natriuretic peptide (BNP) post-treatment relative to pre-treatment, and the incidence of adverse reactions were compared. Results:Total response rate was significantly higher in the observation group than in the control group [94.0% (94/100) vs. 85.0% (85/100), χ2 = 4.31, P < 0.05]. There were no significant differences in CRP, IL-6, TNF-α, LVEF, cTnI, and BNP pre-treatment between the two groups (all P > 0.05). CRP, IL-6, TNF-α post-treatment in the observation group were (56.29 ± 10.78) ng/L, (75.60 ± 13.24) ng/L, (130.42 ± 24.79) ng/L respectively, which were significantly lower than those in the control group [(70.52 ± 13.10) ng/L, (87.46 ± 15.68) ng/L, (164.51 ± 28.47) ng/L, t = 8.38, 5.77, 9.03, all P < 0.001]. LVEF post-treatment was significantly higher in the observation group than in the control group [(58.30 ± 8.65)% vs. (54.29 ± 7.9)%, t = -3.42, P < 0.05]. cTnI and BNP post-treatment in the observation group were (1.87 ± 0.52) μg/L and (218.42 ± 24.23) ng/L, respectively, which were significantly lower than those in the control group [(2.40 ± 0.65) μg/L, (325.61 ± 36.97) ng/L, t = 6.36, 24.25, both P < 0.05]. The incidence of adverse reactions in the observation group was slightly, but not significantly, higher than that in the control group [8.0% (8/100) vs. 6.0% (6/100), P > 0.05]. Conclusion:Xuebijing injection combined with phentolamine and dobutamine is effective in the treatment of severe pneumonia complicated by heart failure. The combined therapy inhibits the expression of inflammatory factors, improves cardiac function, has a low incidence of adverse reactions, and is highly safe.